Skip to main content
American Journal of Public Health logoLink to American Journal of Public Health
letter
. 2022 Jan;112(1):e2–e3. doi: 10.2105/AJPH.2021.306555

Balfour et al. Respond

David J K Balfour 1, Neal L Benowitz 1, Suzanne M Colby 1, Dorothy K Hatsukami 1, Harry A Lando 1, Scott J Leischow 1, Caryn Lerman 1, Robin J Mermelstein 1, Raymond Niaura 1, Kenneth A Perkins 1, Ovide F Pomerleau 1, Nancy A Rigotti 1, Gary E Swan 1, Kenneth E Warner 1,, Robert West 1
PMCID: PMC8713616  PMID: 34936419

Wasim Maziak takes issue with only one of our article’s many topics: youth vaping as a gateway to cigarette smoking. He is correct that we subject the prospective studies to greater scrutiny than we do the articles challenging them. The prospective studies constitute the gateway theory evidence base, yet they have been subjected to relatively little critical examination. Covering as much territory as does our article, we did not have space to analyze every cited article. But as with each subject we consider, we provide ample references from which readers can draw their own conclusions.

Maziak asserts that the authors “also ignored studies that addressed their critiques of the gateway effect—by having a longitudinal design, adjusting for other tobacco and substance use, and examining regular cigarette smoking rather than experimentation—and still revealed the same association.” He cites one study1 of which we were unaware. We had found only three studies2–4 that included other tobacco use. Only one of these4 also included marijuana, although solely in a sensitivity analysis in supplementary material. In the article’s text referring to this sensitivity analysis, the authors wrote that vaping-smoking “[a]ssociations decreased in magnitude with adjustment for marijuana use.”4(p184) They failed to mention that the association with past 30-day smoking became nonsignificant. Similarly, as noted in our article, two articles by Wills et al.,5,6 using the identical data set, demonstrate that the inclusion of marijuana and three other variables5 eliminates the statistically significant relationship between vaping and subsequent smoking reported in the article that omitted these variables.6

Maziak considers the authorship of our article “unbalanced” because we believe there is substantial evidence that vaping can help some adult smokers to quit smoking, and that this can improve public health. We provide substantial documentation. Having devoted our careers to the welfare of both youth and adult smokers, we call for a more balanced consideration of the impacts of vaping because both are important and the current fervent emphasis on youth may come at a potentially significant cost to adult smokers. The powerful influence on the media and legislators of well-funded organizations like the Campaign for Tobacco Free Kids7 and the Truth Initiative,8 singularly focused on youth vaping, belies Maziak’s claim that “adolescents are a vulnerable population without a legal and political voice.” One could argue that the marginalized populations comprising adult smokers are the vulnerable groups lacking a political voice.

CONFLICTS OF INTEREST

N. L. Benowitz is a consultant to Pfizer and Achieve Life Sciences, companies that market or are developing smoking cessation medications, and has been an expert witness in litigation against tobacco companies. S. J. Leischow is conducting a clinical trial supported by Achieve Life Sciences, which is developing a nonnicotine medication for smoking cessation, and has consulted with them. He also consulted more than one year ago for GSK, which is working to bring a new nicotine replacement product to market, and he receives medication for a National Institutes of Health–funded smoking-cessation study from Pfizer. N. A. Rigotti receives royalties from UpToDate Inc for writing about smoking cessation and e-cigarettes and is a consultant for Achieve Life Sciences for an investigational smoking-cessation medication. R. West has undertaken research and consultancy for Pfizer and GSK, companies that manufacture smoking-cessation medications.

REFERENCES


Articles from American Journal of Public Health are provided here courtesy of American Public Health Association

RESOURCES